SCHEMBL3877376

SCHEMBL3877376

N#Cc1cccc(-c2nc(N3CCOCC3)nc(N3CCN(c4ncccc4C(F)(F)F)CC3)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.52
PIK3CG P48736 1/20 0.52
PDE4D Q08499 1/20 0.49
HSD11B1 P28845 1/20 0.48
HRH4 Q9H3N8 1/20 0.48
TRPV1 Q8NER1 6/20 0.47
MTOR P42345 2/20 0.47
LRRK2 Q5S007 2/20 0.45
MST1 P26927 1/20 0.45
STK4 Q13043 1/20 0.45
STK3 Q13188 1/20 0.45
STK26 Q9P289 1/20 0.45
ATM Q13315 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3880603 0.92 HSD11B1 (0.50) HSD11B1HRH4TRPV1CYP1A2CYP3A4
SCHEMBL3881365 0.90 HSD11B1 (0.55) PIK3CAPIK3CGHSD11B1TRPV1MTOR
SCHEMBL3879917 0.88 PDE4D (0.53) PIK3CAPIK3CGPDE4DHSD11B1TRPV1
SCHEMBL3877122 0.88 PDE4D (0.53) PIK3CAPIK3CGPDE4DHSD11B1TRPV1
SCHEMBL3876757 0.87 MTOR (0.53) PIK3CAHSD11B1TRPV1MTORATM
SCHEMBL3878211 0.87 NPSR1 (0.57) HSD11B1TRPV1MTORATMNPSR1
SCHEMBL3882297 0.86 NPSR1 (0.54) HSD11B1TRPV1MTORATMNPSR1
SCHEMBL3885543 0.86 HSD11B1 (0.52) HSD11B1HRH4TRPV1NPSR1
SCHEMBL3876846 0.86 MTOR (0.49) PIK3CAHSD11B1HRH4TRPV1MTOR
SCHEMBL3877647 0.86 HSD11B1 (0.52) PIK3CAHSD11B1TRPV1MTORATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US claimed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues GPR174, GPR68, PPARG PIK3CA 1107/4885PIK3CG 2221/4885PDE4D 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.